Jill Milne
Principal executive officer pay for Jill Milne, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Astria Therapeutics, Inc. (ATXS) FY2021–FY2024
Aligned: paid up as stock roseCAP $1,256,212→$8,962,336 while $100 invested went $42.00→$166.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $3.4M | $1.3M |
| FY2022 | $1.7M | $4.6M |
| FY2023 | $3.0M | $2.1M |
| FY2024 | $6.6M | $9.0M |
The company's "$100 invested" index ran $42.00 at FY2021 → $166.00 by FY2024 — an annualized return of 58.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 58.1%/yr at ATXS ( FY2021–FY2024). See the CEO track-record ranking for context.